



**ONE MINUTE**  
**YOU'RE HAVING THE**  
**TIME OF YOUR LIFE.**

**24 HOURS LATER,**  
**YOU COULD BE**  
**FIGHTING FOR IT.**

# NOW IS THE TIME TO LEARN 4 FACTS ABOUT INVASIVE MENINGOCOCCAL DISEASE (IMD)



Meningococcal (Groups A,C,Y and W-135)  
Polysaccharide Diphtheria Toxoid Conjugate Vaccine

1

Crowded settings (such as **universities, colleges, night clubs, bars, pubs and concerts**) pose a higher risk for IMD transmission. Also at greater risk are students living in close quarters like **campus dorms**, or participating in **sports teams** or **summer camps**.

2

IMD is fast-moving and can be fatal within just 24 hours. Of those who survive, up to 19% become permanently disabled.

3

It is contagious and passed on through contact with saliva – this includes kissing, or simply sharing a cigarette or drink.

4

You can protect yourself by getting vaccinated.

**Ask your healthcare provider about MENACTRA®.**

To learn more about IMD and how you can help protect yourself, visit: **menactra.ca**

MENACTRA® is a vaccine for the prevention of meningococcal meningitis and other invasive meningococcal diseases caused by *Neisseria meningitidis* (serogroups A, C, Y, and W-135) in persons 9 months through 55 years old. MENACTRA® is not indicated for the prevention of invasive meningococcal disease caused by serogroup B. MENACTRA® is not to be used for the treatment of meningococcal infections, and cannot prevent complications or death after the onset of the disease. Persons previously diagnosed with GBS may be at increased risk of GBS following receipt of MENACTRA®. As with any vaccine, MENACTRA® may not protect 100% of vaccinated individuals. Adverse reactions and side effects may occur. The most common side effects in adolescents and adults (11-55 years old) are pain, redness and induration at the injection site, headache, fatigue and malaise. Talk to your healthcare provider to see if MENACTRA® is right for you.

Consult with your private insurance plan for MENACTRA® coverage information. Drug Identification Number (DIN): 02279924.

For complete product information, visit [products.sanofi.ca/en/menactra.pdf](http://products.sanofi.ca/en/menactra.pdf).



MENACTRA® is a registered trademark of Sanofi Pasteur. © 2019 Sanofi Pasteur Limited. All rights reserved.  
SPCA.MENAC.19.07.0037 E

